—Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — TOKYO — PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as “PHC”), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; […]
PHC and Cyfuse have developed a new production technology for commercializing 3D cell products by combining Cyfuse's Bio 3D Printing with PHC's in-line monitoring technology. This advancement allows real-time quality monitoring and more stable manufacturing of 3D cell products. They aim to develop a circulation cell culture system incorporating this technology. The findings will be presented at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine.
